SCHEMBL1189753

SCHEMBL1189753

O=C1CN(Cc2ccccc2)C(=O)C12CC2

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.61
MEN1 O00255 2/20 0.61
ELANE P08246 3/20 0.47
EPHX2 P34913 1/20 0.46
DDB1 Q16531 1/20 0.46
CRBN Q96SW2 1/20 0.46
OPRM1 P35372 5/20 0.44
OPRK1 P41145 5/20 0.44
OPRL1 P41146 5/20 0.44
HPGD P15428 1/20 0.44
TSHR P16473 1/20 0.44
RIPK1 Q13546 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.42
POLB P06746 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
F2 P00734 1/20 0.41
PLG P00747 1/20 0.41
CTSG P08311 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12491711 0.93 KMT2A (0.67) KMT2AMEN1ELANEEPHX2DDB1
SCHEMBL16835494 0.93 KMT2A (0.67) KMT2AMEN1ELANEEPHX2DDB1
SCHEMBL3189921 0.83 MEN1 (0.46) KMT2AMEN1OPRM1TSHRL3MBTL1
SCHEMBL3207582 0.83 ELANE (0.56) KMT2AMEN1ELANEEPHX2DDB1
SCHEMBL12247772 0.80 KMT2A (0.54) KMT2AMEN1ELANEEPHX2DDB1
SCHEMBL8775328 0.80 KMT2A (0.54) KMT2AMEN1ELANEEPHX2DDB1
SCHEMBL8775485 0.80 KMT2A (0.54) KMT2AMEN1ELANEEPHX2DDB1
SCHEMBL1190301 0.76 KMT2A (0.50) KMT2AMEN1ELANEEPHX2DDB1
SCHEMBL1190299 0.76 KMT2A (0.50) KMT2AMEN1ELANEEPHX2DDB1
SCHEMBL9726979 0.76 KMT2A (1.00) KMT2AMEN1ELANEEPHX2DDB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120058589-A Preparation method of sitafloxacin intermediate 5-benzyl-7 (S) -tert-butylcarbonylamino-5-azaspiro [2,4] heptane 甘肃皓天医药科技有限责任公司 2025-05-30 CN claimed
JP-8157455-A None JP disclosed
JP-5221947-A None JP disclosed
JP-11240868-A None JP disclosed
JP-11240867-A None JP disclosed
CN-120058589-A Preparation method of sitafloxacin intermediate 5-benzyl-7 (S) -tert-butylcarbonylamino-5-azaspiro [2,4] heptane 甘肃皓天医药科技有限责任公司 2025-05-30 CN disclosed
CN-120058589-A Preparation method of sitafloxacin intermediate 5-benzyl-7 (S) -tert-butylcarbonylamino-5-azaspiro [2,4] heptane 甘肃皓天医药科技有限责任公司 2025-05-30 CN disclosed
US-10358417-B2 Method for preparing efficiently synthetic sitafloxacin intermediate (7S)-5-azaspiro[2.4]heptane-7-yl tert-butyl carbamate CHEN-STONE (GUANGZHOU) CO., LTD. (CN) 2019-07-23 US disclosed
EP-2217226-B1 PEPTIDE DEFORMYLASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2015-07-22 EP disclosed
WO-2013177092-A1 SUBSTITUTED ALKYNYL PYRIDINE COMPOUNDS AND METHODS OF USE SUNSHINE LAKE PHARMA CO., LTD. (CN) 2013-11-28 WO disclosed
JP-H11240868-A 7-AMIO-5-SUBSTITUTED-5-AZASPIRO(2,4)HEPTANE DERIVATIVE DAI ICHI SEIYAKU CO LTD 1999-09-07 JP disclosed
JP-H11240867-A 5-SUBSTITUTED-4,7-DIOXO-5-AZASPIRO(2,4)HEPTANE DERIVATIVE DAI ICHI SEIYAKU CO LTD 1999-09-07 JP disclosed
EP-0529688-B1 Azaspiro(n,m)alkanes and diazaspiro(n,m)-alkanes DAIICHI SEIYAKU CO (JP) 1997-11-12 EP disclosed
JP-H08157455-A AZASPIRO DERIVATIVE AND ITS PRODUCTION DAI ICHI SEIYAKU CO LTD 1996-06-18 JP disclosed
US-5508428-A Spiro compound DAIICHI PHAMACEUTICAL CO., LTD. (JP) 1996-04-16 US disclosed
US-5286723-A Spiro compound DAIICHI SEIYAKU CO., LTD. 1994-02-15 US disclosed
EP-0357047-B1 Spiro compounds DAIICHI SEIYAKU CO (JP) 1993-11-03 EP disclosed
JP-H05221947-A PRODUCTION OF CYCLOPROPANE DERIVATIVE DAI ICHI SEIYAKU CO LTD 1993-08-31 JP disclosed
EP-0529688-A2 Azaspiro n,m alkanes and diazaspiro n,m -alkanes DAIICHI PHARMACEUTICAL CO., LTD. (JP) 1993-03-03 EP disclosed
EP-0357047-A1 Spiro compounds DAIICHI PHARMACEUTICAL CO., LTD. (JP) 1990-03-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10358417-B2 Method for preparing efficiently synthetic sitafloxacin intermediate (7S)-5-azaspiro[2.4]heptane-7-yl tert-butyl carbamate TYMS, CYP51A1, TPMT KMT2A 2614/4885MEN1 3971/4885ELANE 2519/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.